- Home
- MKTX vs BBIO Comparison
MKTX vs BBIO Comparison
Compare MKTX & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTX
- BBIO
- Stock Information
- Founded
- MKTX 2000
- BBIO 2015
- Country
- MKTX United States
- BBIO United States
- Employees
- MKTX N/A
- BBIO N/A
- Industry
- MKTX Investment Bankers/Brokers/Service
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MKTX Finance
- BBIO Health Care
- Exchange
- MKTX Nasdaq
- BBIO Nasdaq
- Market Cap
- MKTX 8.0B
- BBIO 7.6B
- IPO Year
- MKTX 2004
- BBIO 2019
- Fundamental
- Price
- MKTX $219.78
- BBIO $41.73
- Analyst Decision
- MKTX Buy
- BBIO Strong Buy
- Analyst Count
- MKTX 9
- BBIO 13
- Target Price
- MKTX $241.78
- BBIO $56.67
- AVG Volume (30 Days)
- MKTX 478.0K
- BBIO 2.5M
- Earning Date
- MKTX 08-05-2025
- BBIO 07-31-2025
- Dividend Yield
- MKTX 1.39%
- BBIO N/A
- EPS Growth
- MKTX N/A
- BBIO N/A
- EPS
- MKTX 5.76
- BBIO N/A
- Revenue
- MKTX $815,355,000.00
- BBIO $127,415,000.00
- Revenue This Year
- MKTX $8.27
- BBIO $102.05
- Revenue Next Year
- MKTX $9.86
- BBIO $54.69
- P/E Ratio
- MKTX $38.31
- BBIO N/A
- Revenue Growth
- MKTX 7.33
- BBIO N/A
- 52 Week Low
- MKTX $186.84
- BBIO $21.62
- 52 Week High
- MKTX $296.68
- BBIO $41.90
- Technical
- Relative Strength Index (RSI)
- MKTX 47.73
- BBIO 69.82
- Support Level
- MKTX $220.16
- BBIO $39.65
- Resistance Level
- MKTX $228.16
- BBIO $41.36
- Average True Range (ATR)
- MKTX 4.81
- BBIO 1.51
- MACD
- MKTX -0.12
- BBIO 0.35
- Stochastic Oscillator
- MKTX 45.34
- BBIO 97.37
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.